Tactile Systems Technology of northeast Minneapolis has been a winner for shareholders since it went public in July at a price of $10 per share.
The fast-growing medical products company, which does business as Tactile Medical, raised more than $40 million in its offering. The stock closed Friday at $20.18 per share, a nearly doubling of shareholder value to more than $320 million.
"We felt the timing was right for us to do the IPO given the tremendous growth in the past two-to-three years," CEO Jerry Mattys said last week. "The capital raised not only strengthens our balance sheet, but also provides access to the public markets … greater flexibility to continue on our growth trajectory, and … invest in strategies for future expansion.
"In addition, going public puts Tactile Medical's products and services in the spotlight and better enables us to create awareness of how our solutions can provide significant benefits to the patients who need them."
Tactile, with 275 employees and profitable in the first half of this year on revenue that increased 34 percent to $33.4 million, makes "home-therapy" products such as pneumatic compression devices that help control swollen limbs connected to cancer of the lymph nodes.
Tactile is the rare growth company that has raised capital through an IPO.
In fact, revenue to investment banks from equity offerings is at 20-year lows since 2015.
Why? Cheap debt, due to sustained historically low interest rates, makes borrowing to expand organically or through acquisitions cheaper than paying an investment bank a 7 percent fee of the gross amount raised in an offering. And the scrutiny and volatility of public-stock ownership is avoided.